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Thank you very much for the critical comments. Any
critical comment on the use of GnRH analogs (GnRHa) to
protect fertility during chemotherapy is of great value in
further discussions of the controversial data and the con-
troversial attitudes of endocrinologists and ocologists.
We fully agree with the authors of the letter that several
studies support the efficacy of GnRHa to protect the ova-
ries, which we have also demonstrated in a review sum-
marizing nine studies on the use of GnRHa [1]. We also
agree with the authors that the efficacy of other fertility
preserving techniques such as cryopreservation and trans-
plantation of ovarian tissue need further evaluation and that
their safety has still not absolutely been proven, as stated in
our recent review about cryopreservation of ovarian
tissue [2]. Finally, we are fully aware that GnRHa pro-
vide several additional advantages during chemotherapy
such as reducing the risk of thrombocytopenia-associated
menorrhagia.
However, we do not agree that GnRHa, in combination
with cryopreservation of ovarian tissue and follicular
aspiration, should be offered to all patients. We rather think
that the current status of scientific data needs critical
reflection and consequently, the patients need to be coun-
seled carefully about the pros and cons of all available
technical options, resulting in highly individualized fertil-
ity preservation approaches.
We would like to comment on the letter in detail:
First, as stated in recent reviews, previous studies did
support the efficacy of GnRHa to protect the ovaries [1, 3].
However, the scientific quality of these studies was limited
as none of the studies was randomized.
Four recently published randomized studies have pro-
vided the following data: The study by Badaway et al. [4]
involving 78 breast cancer patients, co-treated with GnRHa
or untreated, revealed regular menstruations in 90 and 33%,
respectively. The study by Ismail-Khan et al. [5], involving
49 breast cancer patients, revealed regular menstruations in
88 and 84%, respectively and the study by Gerber et al. [6]
involving 60 breast cancer patients revealed regular men-
struations in 93 and 97%, respectively. Behringer et al. [7]
analyzed Hodgkin’s lymphoma patients. Eleven patients
were treated with escalated BEACOPP, receiving GnRHa,
and 12 controls with oral contraceptives. They found a
difference neither in the rate of amenorrhea nor in the
concentration of anti-Mullerian hormone.
As only one of these four studies did demonstrate a
GnRHa induced protective effect on the ovaries, it is not
justified to argue that all patients should receive GnRHa.
The only scientifically acceptable conclusions are, first,
that the available data are still controversial, second, that
further studies are needed, and third, that patients can be
offered GnRHa but need to be informed about the con-
troversial data.
Second, we agree with the authors that the safety
and efficacy of cryopreservation of ovarian tissue need
further evaluation. We also support their attitude that
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cryopreservation of ovarian tissue should therefore be
combined with other techniques such as ovarian stimula-
tion and cryopreservation of fertilized and unfertilized
oocytes which can be combined safely and efficiently, as
demonstrated in a recent pilot study [8].
Third, ovarian stimulation and cryopreservation of fer-
tilized and unfertilized oocytes still remains the only tech-
nique that has been proven to be safe and efficient and should
therefore be considered in all patients. New stimulation
protocols allow ovarian stimulation in all patients within
2 weeks irrespective of their menstrual phase [9] and can
even be used for breast cancer patients by using aromatase
inhibitors which reduce estrogen levels [10]. Data of large
registries, i.e. of the network FertiPROTEKT (http://www.
fertiprotekt.eu), have revealed representative data in [200
patients on the age dependant number of collected oocytes
and their fertilization rate following ovarian stimulation
before chemotherapy. These data allow, for the first time,
profound and reliable counseling of patients.
In summary, we believe that the efficacy of GnRHa in
ovarian protection during chemotherapy has still not been
proven. However, they can be offered to patients after
careful counseling. We also think that additional techniques
such as cryopreservation of ovarian tissue and ovarian
stimulation should always be considered as additional
procedures to increase the chance for a future pregnancy.
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